Polycystic ovary syndrome (PCOS) is one of the most common causes of infertility and metabolic problems among women of reproductive age. The mechanism of PCOS is associated with concurrent alterations at the hormonal level. The diagnosis assumes the occurrence of three interrelated symptoms of varying severity, namely ovulation disorders, androgen excess, or polycystic ovarian morphology (PCOM), which all require a proper therapeutic approach. The main symptom seems to be an increased androgen concentration, which in turn may contribute to different metabolic disorders. A number of papers have demonstrated the significant role of inositol therapy in PCOS. However, there is a lack of detailed discussion about the importance of myo-inositol (MI) and d-chiro-inositol (DCI) in reference to particular symptoms. Thus, the aim of this review is to present the effectiveness of MI and DCI treatment for PCOS symptoms. Moreover, the review is focused on analyzing the use of inositols, taking into account their physiological properties, together with the mechanism of individual PCOS symptom formation.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6888190 | PMC |
| http://dx.doi.org/10.3390/ijms20225787 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Association of TCF7L2 genetic variants rs12255372 and rs7903146 with the polycystic ovary syndrome risk: systemic review and meta-analysis.
J Ovarian Res
January 2025
Departments of Endocrinology, Sheri Kashmir Institute of Medical Sciences, Srinagar, J&K, India.
Background: A significant overlap in the pathophysiological features of polycystic ovary syndrome (PCOS) and type 2 diabetes mellitus (T2DM) has been reported; and insulin resistance is considered a central driver in both. The expression and hepatic clearance of insulin and subsequent glucose homeostasis are mediated by TCF7L2 via Wnt signaling. Studies have persistently associated TCF7L2 genetic variations with T2DM, however, its results on PCOS are sparse and inconsistent.
View Article and Find Full Text PDFMedical therapy to treat obesity and optimize fertility in women of reproductive age: a narrative review.
Reprod Biol Endocrinol
January 2025
Departments of Internal Medicine and Obstetrics, Gynecology and Reproductive Sciences, Yale School of Medicine, 330 Cedar St, New Haven, CT, 06510, USA.
Background: Overweight and obesity-chronic illnesses in which an increase in body fat promotes adipose tissue dysfunction and abnormal fat mass resulting in adverse metabolic, biomechanical, and psychosocial health consequences-negatively impact female fertility. Adverse conception outcomes are multifactorial, ranging from poor oocyte quality and implantation issues to miscarriages and fetal health issues. However, with the advent of novel pharmacologic agents, significant weight loss can be achieved, improving the chances of healthy pregnancies, and their use should be considered during periconceptual counseling.
View Article and Find Full Text PDFPolycystic ovary syndrome negatively affects sexual function and lower urinary tract symptoms in syrian women: a case-control study.
Sci Rep
January 2025
Department of Surgery, Faculty of Medicine, Damascus University, Damascus, Syrian Arab Republic.
Polycystic ovary syndrome (PCOS) is the most prevalent endocrine disorder in women of reproductive age worldwide, and its related features like obesity, mental health issues and hyperandrogenism may contribute to inadequately investigated health problems such as sexual dysfunction (SD) and lower urinary tract symptoms (LUTS). Therefore, this study examined the impact of PCOS on sexual function (SF) and lower urinary tract in Syrian women by recruiting a total of 178 women of reproductive age, of whom 88 were diagnosed with PCOS according to the Rotterdam criteria and 90 without PCOS were considered as the control group. Female sexual function index (FSFI) and Bristol Female Lower Urinary Tract Symptom Questionnaire (BFLUTS) were used to assess SF and LUTS respectively.
View Article and Find Full Text PDFA risk prediction model for endometrial hyperplasia/endometrial carcinoma in premenopausal women.
Sci Rep
January 2025
Department of Gynecology, Chongqing Ninth People's Hospital, 69, Jialing Village, Beibei District, Chongqing, 400700, China.
This study investigated the risk factors for endometrial hyperplasia (EH) and endometrial carcinoma (EC) in premenopausal women. The goal was to establish a nomogram model to predict the risk of EH/EC and quantitative standards in clinical practice, which improved the clinical prognosis of EH/EC patients. Data were collected from premenopausal women with suspected EH/EC who underwent hysteroscopic endometrial biopsy.
View Article and Find Full Text PDFProspective associations of adolescent obesity phenotypes with self-reported polycystic ovary syndrome diagnosis in young adulthood.
Hum Reprod
January 2025
Department of Epidemiology, Brown University School of Public Health, Providence, RI, USA.
Study Question: Are empirically derived adolescent overweight/obesity phenotypes differentially associated with polycystic ovary syndrome (PCOS) in young adulthood?
Summary Answer: Self-reported PCOS diagnosis risk in young adulthood varied by empirically derived adolescent overweight/obesity phenotypes, with the highest risk observed among those in the 'mothers with obesity' and 'early puberty' phenotypes.
What Is Known Already: Overweight and obesity during puberty are postulated to promote the development of PCOS. Much of the prior literature in this area is cross-sectional and defines weight status based solely on BMI, yet emerging research suggests that not all people with overweight/obesity have the same risk for chronic health conditions, including PCOS.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!